

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – December 12, 2018 @ 4:00pm

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. November 14, 2018 DUR Minutes – Vote
- B. November 14, 2018 DUR Recommendations Memorandum
- C. Correspondence

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/Chronic Medication Adherence Program Update – See Appendix B

- A. Medication Coverage Activity for November 2018
- B. Pharmacy Helpdesk Activity for November 2018
- C. Chronic Medication Adherence Program Update

Items to be presented by Dr. Ratterman, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Hemlibra[®] (Emicizumab-kxwh), Feiba[®] (Anti-Inhibitor Coagulant Complex), NovoSeven[®] RT [Coagulation Factor VIIa (Recombinant)], and Jivi[®] [Antihemophilic Factor (Recombinant), PEGylated-aucl] – See Appendix C

- A. Introduction
- B. Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Onpatro[™] (Patisiran) and Tegsed[™] (Inotersen) – See Appendix D

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Zemdri[™] (Plazomicin), Xerava[™] (Eravacycline), Nuzyra[™] (Omadacycline), Seysara[™] (Sarecycline), and Ximino[™] (Minocycline Extended-Release) – See Appendix E

- A. Introduction
- B. Cost Comparison: Minocycline Products
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Connell, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Signifor[®] LAR (Pasireotide) – See Appendix F

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize Symdeko® (Tezacaftor/Ivacaftor) and Orkambi® (Lumacaftor/Ivacaftor Oral Granules) and to Update the Kalydeco® (Ivacaftor) Prior Authorization Criteria – See Appendix G

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

10. Annual Review of Maintenance Asthma and Chronic Obstructive Pulmonary Disease (COPD) Medications and 30-Day Notice to Prior Authorize Lonhala® Magnair® (Glycopyrrolate Inhalation Solution), Yupelri™ (Revefenacin Inhalation Solution), and Dupixent® (Dupilumab Injection) – See Appendix H

- A. Current Prior Authorization Criteria
- B. Utilization of Maintenance Asthma and COPD Medications
- C. Prior Authorization of Maintenance Asthma and COPD Medications
- D. Market News and Updates
- E. Lonhala® Magnair® (Glycopyrrolate Inhalation Solution) Product Summary
- F. Yupelri™ (Revefenacin Inhalation Solution) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Maintenance Asthma and COPD Medications
- I. Utilization Details of Inhaled Corticosteroids

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

11. Annual Review of Thrombocytopenia Medications and 30-Day Notice to Prior Authorize Tavalisse™ (Fostamatinib), Doptelet® (Avatrombopag), and Mulpleta® (Lusutrombopag) – See Appendix I

- A. Current Prior Authorization Criteria
- B. Utilization of Thrombocytopenia Medications
- C. Prior Authorization of Thrombocytopenia Medications
- D. Market News and Updates
- E. Tavalisse™ (Fostamatinib) Product Summary
- F. Doptelet® (Avatrombopag) Product Summary
- G. Mulpleta® (Lusutrombopag) Product Summary
- H. College of Pharmacy Recommendations
- I. Utilization Details of Thrombocytopenia Medications

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

12. Annual Review of Inhaled Anti-Infective Medications and 30-Day Notice to Prior Authorize Arikayce® (Amikacin Liposome Inhalation Suspension) – See Appendix J

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Inhaled Anti-Infective Medications
- D. Prior Authorization of Inhaled Anti-Infective Medications
- E. Market News and Updates
- F. Arikayce® (Amikacin Liposome Inhalation Suspension) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Inhaled Anti-Infective Medications

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

13. Annual Review of Anti-Emetic Medications and 30-Day Notice to Prior Authorize Akynzeo® IV (Fosnetupitant/Palonosetron Injection for Intravenous Use) – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Emetic Medications
- C. Prior Authorization Anti-Emetic Medications
- D. Market News and Updates
- E. Cost Comparison
- F. College of Pharmacy Recommendations

G. Utilization Details of Anti-Emetic Medications

Items to be presented by Dr. Connell, Dr. Muchmore, Chairman:

14. 30-Day Notice to Prior Authorize Carbaglu® (Carglumic Acid) – See Appendix L

- A. Introduction
- B. Carbaglu® (Carglumic Acid) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

15. Annual Review of Muscular Dystrophy Medications – See Appendix M

- A. Current Prior Authorization Criteria
- B. Utilization of Muscular Dystrophy Medications
- C. Prior Authorization of Muscular Dystrophy Medications
- D. Market News and Updates
- E. Cost Changes
- F. College of Pharmacy Recommendations

Non-Presentation; Questions Only:

16. Industry News and Updates – See Appendix N

- A. Introduction
- B. News and Updates

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

17. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix O

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

18. Future Business* (Upcoming Product and Class Reviews)

No live meeting scheduled for January. January 2019 will be a packet only meeting.

- A. Glaucoma Medications
- B. Revcovi™ (Elapegedemase-IVlr)
- C. Injectable and Vaginal Progesterone Products
- D. Hyperkalemia Medications
- E. Zilretta® (Triamcinolone Extended-Release Injectable Suspension)

**Future business subject to change.*

19. Adjournment